News roundup
Genetic test can show whether drugs to treat colon cancer will work
Quebec David Spurgeon
A new study indicates that a simple genetic test can determine whether
chemotherapy will be effective in treating colon cancer, the fourth commonest
cancer in developed countries and the second leading cause of death from cancer
in North America.
The study, led by doctors and researchers from Princess Margaret Hospital and
Mount Sinai Hospital, Toronto, and involving other researchers in the United
States and France, showed that patients with a mutation in their tumours did not
benefit from chemotherapy, which can cause major unpleasant side effects (N
Engl J Med 2003;349:247-57).
The mutation is called high frequency microsatellite instability.
Microsatellites are stretches of DNA in which a short motif, usually one to five
nucleotides long, is repeated several times. Microsatellite instability occurs
when a germ line microsatellite allele has gained or lost repeated units.
The studys lead author, Dr Steven Gallinger, a surgical oncologist at the
Mount Sinai Hospital and University health network and a professor of surgery at
the University of Toronto, said, "This study shows that the usual type of
chemotherapy is effective for about 83% of colon cancer patients. Yet for nearly
17% of colon cancer patients the traditional chemotherapy treatment is not
helpful and may even be harmful."
To conduct the investigation, tumour specimens were collected from patients
with colon cancer who were enrolled in randomised trials of flourouracil based
adjuvant chemotherapy.
The benefit of treatment differed significantly according to the
microsatellite-instability status (P=0.01). Adjuvant chemotherapy improved
overall survival among patients with microsatellite-stable tumours or tumours
exhibiting low-frequency microsatellite instability, according to a multivariate
analysis adjusted for stage and grade (hazard ratio for death, 0.72 [95 percent
confidence interval, 0.53 to 0.99]; P=0.04). By contrast, there was no benefit
of adjuvant chemotherapy in the group with high-frequency microsatellite
instability.
Dr Malcolm Moore, a medical oncologist at Princess Margaret Hospital, said,
"Undergoing chemotherapy is not an easy decision. Side effects can include sore
throat and mouth, tiredness, increased risk of infection, and, in a small number
of cases . . . serious life threatening illness. If we can select the patients
most likely to benefit from therapy, we can restrict therapy to that population
and spare the remaining patients the trauma of that type of treatment."
However, their report does not advocate altering clinical decision making on
the basis of their findings: "If confirmed by other analyses of previous,
well-designed clinical trials or by future prospective, randomised, controlled
studies . . . our findings would indicate that microsatellite-instability
testing should be conducted routinely and the results used to direct rational
adjuvant chemotherapy in colon cancer."
An accompanying article (2003;349:209-210) says that testing for the mutation
is straightforward: "DNA from the tumor and from normal tissue (blood, a buccal
smear, or normal colonic mucosa) is tested by genotyping fluorescently labelled
polymerase-chain-reaction products with the use of an automatic sequencer. A
panel of five microsatellite markers is usually enough; microsatellite
instability in two or more of them is a positive result."
Not only could such tests help doctors assess a patients prognosis and
perhaps guide treatment, they could be a powerful method of screening for
hereditary non-polyposis colorectal cancer, says the author of the accompanying
article, Dr Albert de la Chapelle, of the human cancer genetics programme at
Ohio State Universitys Comprehensive Cancer Centre.